China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$3.00+0.27 (+9.89%)
Close on Nov 13, 2026Market cap $2.87MP/E –Yield –
China SXT Pharmaceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$9.13. The highest annual figure on record is $1.66 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$9.13 | – |
| FY2025 | Mar 31, 2025 | -$348.17 | – |
| FY2024 | Mar 31, 2024 | -$4285.66 | – |
| FY2023 | Mar 31, 2023 | -$177.84 | – |
| FY2022 | Mar 31, 2022 | -$137.92 | – |
| FY2021 | Mar 31, 2021 | -$3.82 | -329.5% |
| FY2020 | Mar 31, 2020 | $1.66 | – |
| FY2019 | Mar 31, 2019 | -$0.30 | -226.7% |
| FY2018 | Mar 31, 2018 | $0.24 | 0.0% |
| FY2017 | Mar 31, 2017 | $0.24 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?